Marta Bonet1, Virginia García1, Núria Farré2, Manel Algara3, Blanca Farrús4, Jaume Fernandez5, Victoria Reyes6, Arancha Eraso7, Ana Álvarez8, Maria José Cambra9, Agustí Pedro10, Jordi Vayreda11, Claire Lemansky12, Françoise Izar13, Meritxell Arenas14. 1. Department of Radiation Oncology, Hospital Universitari Arnau de Vilanova, Lleida, Spain. 2. Department of Radiation Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 3. Department of Radiation Oncology, Parc de Salut Mar, Barcelona, Spain. 4. Department of Radiation Oncology, Hospital Clínic, Barcelona, Spain. 5. Department of Radiation Oncology, Hospital Quirón, Barcelona, Spain. 6. Department of Radiation Oncology, Hospital de la Vall d'Hebron, Barcelona, Spain. 7. Department of Radiation Oncology, Institut Català d'Oncologia - Hospital Duran i Reynals, Barcelona, Spain. 8. Department of Radiation Oncology, Institut Català d'Oncologia - Hospital Germans Trias i Pujol, Badalona, Spain. 9. Hospital General de Catalunya, Institut Oncològic del Vallès, Sant Cugat, Spain. 10. Department of Radiation Oncology, Hospital Plató, Barcelona, Spain. 11. Department of Radiation Oncology, Institut Català d'Oncologia - Hospital Josep Trueta, Girona, Spain. 12. Department of Radiation Oncology, Institut de Cancérologie de Montpellier - Val d'Aurelle, University of Montpellier, France. 13. Department of Radiation Oncology, Institut Universitaire du Cancer de Toulouse, Toulouse, France. 14. Department of Radiation Oncology, Hospital Universitari Sant Joan de Reus, Tarragona, Spain.
Abstract
INTRODUCTION: The role of radiation therapy (RT) for patients with bone-only metastatic (BOM) breast cancer has not been investigated sufficiently. The aim of this survey was to evaluate current clinical practice in treating breast cancer patients with BOM in Radiation Therapy Departments in Catalonia and Occitania within the scope of the GOCO group. MATERIALS AND METHODS: An electronic questionnaire was completed by experienced radiation oncologists from fourteen RT centers. The items surveyed the professional experience, therapeutic approach, technique, dose stereotactic body RT (SBRT) availability. RESULTS: All Radiation Oncology Departments (ROD) in Catalonia (12) and Occitania (2) responded to the survey. Eleven (78.5%) of the RODs advise RT for BOM as initial treatment in the oligometastatic setting. RT to asymptomatic bone oligometastases is more often restricted for "risky lesions". The most inconsistent approaches were the treatment for asymptomatic lesions, when to treat bone metastases with respect to systemic treatment (ST) and the indication for RT after a complete response to ST. CONCLUSION: While BOM breast cancer patients have a relatively good prognosis, there is a lack of consistency in their approach with RT. This can be explained by the absence of evidence-based guidelines and an incomplete availability of SBRT.
INTRODUCTION: The role of radiation therapy (RT) for patients with bone-only metastatic (BOM) breast cancer has not been investigated sufficiently. The aim of this survey was to evaluate current clinical practice in treating breast cancer patients with BOM in Radiation Therapy Departments in Catalonia and Occitania within the scope of the GOCO group. MATERIALS AND METHODS: An electronic questionnaire was completed by experienced radiation oncologists from fourteen RT centers. The items surveyed the professional experience, therapeutic approach, technique, dose stereotactic body RT (SBRT) availability. RESULTS: All Radiation Oncology Departments (ROD) in Catalonia (12) and Occitania (2) responded to the survey. Eleven (78.5%) of the RODs advise RT for BOM as initial treatment in the oligometastatic setting. RT to asymptomatic bone oligometastases is more often restricted for "risky lesions". The most inconsistent approaches were the treatment for asymptomatic lesions, when to treat bone metastases with respect to systemic treatment (ST) and the indication for RT after a complete response to ST. CONCLUSION: While BOM breast cancer patients have a relatively good prognosis, there is a lack of consistency in their approach with RT. This can be explained by the absence of evidence-based guidelines and an incomplete availability of SBRT.
Authors: Karin Kast; Theresa Link; Katrin Friedrich; Andrea Petzold; Antje Niedostatek; Olaf Schoffer; Carmen Werner; Stefanie J Klug; Andreas Werner; Axel Gatzweiler; Barbara Richter; Gustavo Baretton; Pauline Wimberger Journal: Breast Cancer Res Treat Date: 2015-03-18 Impact factor: 4.872
Authors: Mellissa Yong; Annette Östergaard Jensen; Jacob Bonde Jacobsen; Mette Nørgaard; Jon P Fryzek; Henrik Toft Sørensen Journal: Breast Cancer Res Treat Date: 2011-04-02 Impact factor: 4.872
Authors: Rifat Atun; David A Jaffray; Michael B Barton; Freddie Bray; Michael Baumann; Bhadrasain Vikram; Timothy P Hanna; Felicia M Knaul; Yolande Lievens; Tracey Y M Lui; Michael Milosevic; Brian O'Sullivan; Danielle L Rodin; Eduardo Rosenblatt; Jacob Van Dyk; Mei Ling Yap; Eduardo Zubizarreta; Mary Gospodarowicz Journal: Lancet Oncol Date: 2015-09 Impact factor: 41.316
Authors: Andrew J Bishop; Joe Ensor; Stacy L Moulder; Simona F Shaitelman; Mark A Edson; Gary J Whitman; Sandra Bishnoi; Karen E Hoffman; Michael C Stauder; Vicente Valero; Thomas A Buchholz; Naoto T Ueno; Gildy Babiera; Wendy A Woodward Journal: Cancer Date: 2015-09-08 Impact factor: 6.860
Authors: Sean E McGuire; Ana M Gonzalez-Angulo; Eugene H Huang; Susan L Tucker; Shu-Wan C Kau; Tse-Kuan Yu; Eric A Strom; Julia L Oh; Wendy A Woodward; Welela Tereffe; Kelly K Hunt; Henry M Kuerer; Aysegul A Sahin; Gabriel N Hortobagyi; Thomas A Buchholz Journal: Int J Radiat Oncol Biol Phys Date: 2007-04-06 Impact factor: 7.038
Authors: Naoki Niikura; Jun Liu; Naoki Hayashi; Shana L Palla; Yutaka Tokuda; Gabriel N Hortobagyi; Naoto T Ueno; Richard L Theriault Journal: Oncologist Date: 2011-01-25